Targeting transforming growth factor beta receptor 1 (TGFβR1) in combination with gemcitabine increases drug perfusion into the tumor core and improves the therapeutic efficacy in pancreatic cancer (100). This evidence concerns the gene TGFBR1 and pancreatic neoplasm.